CfA seminar: The airway microbiome and severe asthma
Prof. Peter Howarth, Faculty of Medicine, University of Southampton and NIHR Respiratory Biomedical Research Unit, Southampton General Hospital, United Kingdom
Host: Sven-Erik Dahlén, Institute of Environmental Medicine
Coffee and tea served 15:30
About the speaker:
Peter Howarth is Professor of Allergy and Respiratory Medicine and Honorary Consultant Physician within Medicine at the University of Southampton. He is a world-leading clinician scientist with a research focus on asthma, particularly severe asthma, and allergy. Much of this work makes use of direct airway sampling at bronchoscopy to obtain samples for the evaluation of the airway microbiome, airway inflammatory status, airway remodelling and to obtain samples for ex vivo cell culture studies. On-going work includes biomarkers for precision medicine of new biologic treatments and evaluation of novel approaches to lung imaging in airways disease. He has contributed much to EU-funded collaborative programmes, such as BIOAIR, GA2LEN, and the EU/EFPIA funded IMI programme U-BIOPRED on severe asthma. In particular, Professor Howarth has created the Wessex Severe Asthma Cohort, a well-characterised group of over 300 patients with treatment-resistant asthma, established to facilitate basic science and interventional studies in severe asthma.
Professor Howarth has published about 250-300 peer reviewed papers and lectured extensively.
Some key publications:
Grainge CL et al. Effect of bronchoconstriction on airway remodelling in asthma. N Engl J Med. 2011;364:2006-15.
This highly cited paper showed that bronchoconstriction by itself causes some of the pathology in asthma normally explained by immune-driven reactions
Wilson SJ et al. Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study. Eur Respir J. 2016;48:1307-1319.
This is the largest histological study of the airway pathology in bronchial biopsies from asthmatics ever conducted (158 subjects). The results highlight that effective anti-inflammatory treatment may reduce tissue inflammation without curing clinical severity.
Hinks TS et al. Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol. 2016;138:61-75.
This multiomics study identifies key biomarkers of asthma sub-phenotypes in blood and sputum.
Singhania A et al. Multitissue Transcriptomics Delineates the Diversity of Airway T Cell Functions in Asthma. Am J Respir Cell Mol Biol. 2018;58:261-270.
This multiomics study identifies key biomarker of asthma sub-phenotypes in bronchial epithelial bruschings, brochioalveloar lavage fluid and sputum.